Skip to content
Kyprolis(carfilzomib)
Kyprolis (carfilzomib) is a protein pharmaceutical. Carfilzomib was first approved as Kyprolis on 2012-07-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target proteasome subunit beta type-5.
Download report
Favorite
Case Study: Multiple Myeloma
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Kyprolis (generic drugs available since 2019-09-09)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carfilzomib
Tradename
Company
Number
Date
Products
KYPROLISOnyx PharmaceuticalsN-202714 RX2012-07-20
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
kyprolisNew Drug Application2021-03-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple myeloma—D009101C90.0
Agency Specific
FDA
EMA
Expiration
Code
CARFILZOMIB, KYPROLIS, ONYX THERAP
2023-08-20I-842
Patent Expiration
Patent
Expires
Flag
FDA Information
Carfilzomib, Kyprolis, Onyx Therap
94935822033-02-27DP
RE479542029-10-21U-3449
95111092029-10-21U-1924
77371122027-12-07DP
74170422026-07-20DS, DP
72328182025-04-14DS, DP
74917042025-04-14U-1260, U-2319, U-2320, U-2947
81293462025-04-14U-1260, U-2319, U-2320, U-2947
82071252025-04-14DS, DP
82071262025-04-14DP
82071272025-04-14U-1260, U-2319, U-2320, U-2947
82072972025-04-14DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XG: Proteasome inhibitors, antineoplastic agent
— L01XG02: Carfilzomib
HCPCS
Code
Description
J9047
Injection, carfilzomib, 1 mg
Clinical
Clinical Trials
208 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.062932328155
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Waldenstrom macroglobulinemiaD008258C88.0131——5
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.972———8
NeoplasmsD009369C8063———7
Non-hodgkin lymphomaD008228C85.951———5
Large b-cell lymphoma diffuseD016403C83.341———4
Smoldering multiple myelomaD000075122—4———4
Hodgkin diseaseD006689C8131———3
T-cell lymphoma peripheralD016411C84.931———3
RecurrenceD01200812———2
Mantle-cell lymphomaD020522C83.111———2
AmyloidosisD000686EFO_1001875E8521———2
Show 11 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938C952————2
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.02————2
Myeloid leukemia acuteD015470C92.01————1
Breast neoplasmsD001943EFO_0003869C501————1
Mycosis fungoidesD009182C84.01————1
PlasmacytomaD010954C90.31————1
Follicular lymphomaD008224C821————1
AnemiaD000740EFO_0004272D64.91————1
Hepatic insufficiencyD0485501————1
Chronic kidney failureD007676EFO_0003884N18.61————1
Show 6 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCARFILZOMIB
INNcarfilzomib
Description
Carfilzomib is a synthetic tetrapeptide consisting of morpholin-4-acetyl, L-2-amino-4-phenylbutanoyl, L-leucyl and L-phenylalanyl residues joined in sequence with the C-terminus connected to the amino group of (2S)-2-amino-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-1-one via an amide linkage. Used for the treatment of patients with multiple myeloma It has a role as an antineoplastic agent and a proteasome inhibitor. It is a tetrapeptide, a member of morpholines and an epoxide.
Classification
Small molecule
Drug classproteozome inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1
Identifiers
PDB—
CAS-ID868540-17-4
RxCUI1302966
ChEMBL IDCHEMBL451887
ChEBI ID65347
PubChem CID11556711
DrugBankDB08889
UNII ID72X6E3J5AR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PSMB5
PSMB5
Organism
Homo sapiens
Gene name
PSMB5
Gene synonyms
LMPX, MB1, X
NCBI Gene ID
5693
Protein name
proteasome subunit beta type-5
Protein synonyms
Macropain epsilon chain, Multicatalytic endopeptidase complex epsilon chain, proteasome (prosome, macropain) subunit, beta type, 5, proteasome beta 5 subunit, proteasome catalytic subunit 3, Proteasome chain 6, Proteasome epsilon chain, proteasome subunit beta 5, Proteasome subunit MB1, Proteasome subunit X, proteasome subunit, beta type, 5, PSX large multifunctional protease X, testicular tissue protein Li 153
Uniprot ID
P28074
Mouse ortholog
Psmb5 (19173)
proteasome subunit beta type-5 (Q9R1P2)
Variants
Clinical Variant
No data
Financial
Kyprolis - Ligand Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Kyprolis - Amgen
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Kyprolis - Onyx Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,404 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
768 adverse events reported
View more details